HCPLive Network

Atherosclerosis

The ACC/AHA cholesterol guideline can be a powerful tool for making multifactorial measures of cardiovascular disease risk assessment, particularly in African American populations, but clinicians should be aware of its limitations.
Several studies have shown good results with Roux-en-Y gastric bypass and laparoscopic gastric banding when combined with lifestyle modifications in severely overweight patients with type 2 diabetes.
To produce the greatest impact from the implementation of the new American College of Cardiology and American Heart Association guidelines for the treatment of hypercholesterolemia in the primary prevention of cardiovascular disease (CVD), physicians should counsel patients on the benefits and risks of medication intervention to prevent CVD, but also explain the absolute necessity of regular exercise and abstention from tobacco use.
There may a point of diminishing health returns with running, according to research findings presented Sunday at the annual meeting of the American College of Cardiology, held from March 29 to 31 in Washington, DC.
Darapladib, a novel agent targeting an enzyme known to be associated with increased instability of atherosclerotic plaque, failed to show real-world benefit in a large global trial examining mortality and coronary outcomes.
Study results presented at ACC.14 show treatment with PCSK9 inhibitor evolocumab significantly reduces LDL-cholesterol levels in patients with hypercholesterolemia.
Atherosclerosis Resources
$AD300x250BB$